[Analphlipoproteinemia and chronic lymphocytic leukemia]

Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers.

Bone marrow transplantation·2013

Myeloma cells suppress osteoblasts through sclerostin secretion.

Blood cancer journal·2012

Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia.

Oncogene·2010

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.

Leukemia·2009

Subsets of CD34+ and early engraftment kinetics in allogeneic peripheral SCT for AML.

Bone marrow transplantation·2008

Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.

Annals of hematology·2007

Response to Comment on: "Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential".

Haematologica·2026

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Haematologica·2026

Response to Comment on: "SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia".

Haematologica·2026

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

Haematologica·2026

ATRA resistance conferred by a clustered subset of hotspot PML::RARA mutations enhancing basal repression rather than precluding transactivation.

Haematologica·2026

Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.

Haematologica·2026

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

British journal of haematology·2026

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

British journal of haematology·2026

Cytodiagnostic features of angiofibroma of soft tissue: A review of 16 cases to identify characteristic findings and their diagnostic significance.

Cancer cytopathology·2026

KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications.

Haematologica·2026

Related Experiment Videos

[Analphlipoproteinemia and chronic lymphocytic leukemia]

Related Concept Videos

Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers.

Myeloma cells suppress osteoblasts through sclerostin secretion.

Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia.

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.

Subsets of CD34+ and early engraftment kinetics in allogeneic peripheral SCT for AML.

Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.

Response to Comment on: "Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential".

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Response to Comment on: "SLC25A1 reprograms mitochondrial and fatty acid metabolism to promote the progression of acute myeloid leukemia".

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

ATRA resistance conferred by a clustered subset of hotspot PML::RARA mutations enhancing basal repression rather than precluding transactivation.

Prognostic relevance of RUNX1 mutations at acute myeloid leukemia diagnosis and as measurable residual disease marker before and after allogeneic stem cell transplantation.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

Cytodiagnostic features of angiofibroma of soft tissue: A review of 16 cases to identify characteristic findings and their diagnostic significance.

KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications.

Related Experiment Videos

[Analphlipoproteinemia and chronic lymphocytic leukemia]

Related Concept Videos

Related Articles